Moxifloxacin: a review of its use in the management of bacterial infections.
Keating
Gillian M
GM
Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Scott
Lesley J
LJ
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D019540:Area Under Curve; D001372:Aza Compounds / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001682:Biological Availability; D029481:Bronchitis, Chronic / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy; D024841:Fluoroquinolones; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011014:Pneumonia / Q000188:drug therapy*; D011804:Quinolines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D014018:Tissue Distribution; D059005:Topoisomerase II Inhibitors
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D059005:Topoisomerase II Inhibitors; D000077266:Moxifloxacin